Preclinical Evaluation of Berry Extracts as a Nutritional Intervention to Alleviate Myocardial Ischemia–Reperfusion Injury and Atherosclerosis Development
Rattachement africain : gr, es, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. While studies suggest that berry fruits offer beneficial effects in CVD prevention, the bioactive compounds within different berries vary, and the specific mechanisms behind their protective effects are not yet fully elucidated. Our study aimed to evaluate and compare the cardioprotective and anti‐atherosclerotic effects of Morus alba (white mulberries, WMex) and Vaccinium myrtillus L. fruit extracts (blueberries, BBex), focusing on acute myocardial infarction (AMI), CVD risk factors, atherosclerosis development, and the underlying mechanisms. WMex and BBex were produced and their qualitative compositions were characterized. We evaluated the infarct size (IS) limiting potential of 8‐weeks supplementation with both WMex and BBex at nutritional doses in mice with western diet (WD)‐induced metabolic syndrome (MS). We further evaluated atherosclerosis development mitigation after 4‐weeks supplementation with the extracts in both male and female WD‐fed ApoE −/− mice as well as the putative cardioprotective and atheroprotective mechanisms. The total flavonoids in WMex and BBex were 49.50 and 98.92 mg rutin/g extract, respectively, while the total phenolic content was 50.74 and 110.00 mg gallic acid/g extract, respectively. Both extracts limited IS compared to Control by suppressing apoptosis. WMex upregulated endothelial nitric oxide synthase (eNOS) phosphorylation and pathway along with circulating nitrite levels. WMex suppressed the extent of atheromatic area in both male and female ApoE −/− mice, while BBex was effective in females without any of the extracts affecting estrogen levels. WMex downregulated NF‐kB‐ICAM‐1 axis in the atherosclerotic area and reduced circulating triglyceride levels. None of the extracts caused signs of toxicity, supporting a safety profile. In conclusion, WMex exerts potent cardioprotective and anti‐atherosclerotic properties in vivo and could be further exploited for CVD prevention.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Preclinical Evaluation of Berry Extracts as a Nutritional Intervention to Alleviate Myocardial Ischemia–Reperfusion Injury and Atherosclerosis Development
- Date Crossref
- 29/05/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National and Kapodistrian University of Athens Laboratory of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Biomedical Research Foundation of the Academy of Athens pays non établi dans la noticeOrganisation à but non lucratif
-
Academy of Athens Histochemistry Unit pays non établi dans la noticeUniversité ou école supérieure
-
Uni Pharma (Greece) pays non établi dans la noticeEntreprise
-
Hospital de Sant Pau pays non établi dans la noticeÉtablissement de santé
-
Biomedical Research Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Uni‐Pharma S.A. Athens Greece pays non établi dans la noticeInstitution
-
Research Institute Sant Pau pays non établi dans la noticeStructure de recherche
Laboratory of Pharmacology — National and Kapodistrian University of Athens, Biomedical Research Foundation of the Academy of Athens et Histochemistry Unit — Academy of Athens, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.